Participants in the top row had fellow eyes that had received anti-vascular endothelial growth factor (VEGF) treatment for neovascular disease during and/or before entering the study. Participants in the bottom row had fellow eyes that were non-neovascular and therefore never received anti-VEGF. Participants with treated neovascular fellow eyes Participant 1 Participant 2 Participant 3 Participant 4 4.5 √Geographic atrophy area (mm) 3.0 1.6-3.0 4.0 2.5 1.2 2.0 3.5 2.0-0.8 SE/FE 1.5 SE/FE SE/EE SE/FE 3.0-²28/0 [§]21/0 14/3 1.0 1.0 Year Year Year Year Participants with non-neovascular fellow eyes Participant 5 Participant 6 Participant 7 Key 4.4 6.0-3.0-→ Study Eye (SE) 4.0 - • - Fellow Eye (FE) 4.0 2.0-3.6 # of injections received 2.0 1.0-SE/FE SE/FE SE/FE 3.2 while enrolled in study

*9*18/0

Year

4/0

Year

8/0

Year

Ó

Figure 4. Plots of geographic atrophy (GA) growth in 7 participants with bilateral GA.